Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v1-EN
Language French English
Date Updated 2024-10-15 2024-10-15
Drug Identification Number 02025248 02025248
Brand name NOVOLIN GE 30/70 PENFILL NOVOLIN GE 30/70 PENFILL
Common or Proper name NOVOLIN GE 30/70 PENFILL NOVOLIN GE 30/70 PENFILL
Company Name NOVO NORDISK CANADA INC NOVO NORDISK CANADA INC
Ingredients INSULIN ISOPHANE HUMAN BIOSYNTHETIC INSULIN INJECTION HUMAN BIOSYNTHETIC INSULIN ISOPHANE HUMAN BIOSYNTHETIC INSULIN INJECTION HUMAN BIOSYNTHETIC
Strength(s) 70UNIT 30UNIT 70UNIT 30UNIT
Dosage form(s) SUSPENSION SUSPENSION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 5 5
ATC code A10AD A10AD
ATC description INSULINS AND ANALOGUES INSULINS AND ANALOGUES
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2025-12-31 2025-12-31
Actual discontinuation date
Remaining supply date 2025-12-31 2025-12-31
Discontinuation status To be discontinued To be discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments
Health Canada comments